AZN

$191.29

Post-MarketAs of Mar 17, 8:00 PM UTC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$191.29
Potential Downside
22.7%
Whystock Fair Value$147.83
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - General

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$296.55B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.20
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Strong income play. Yield provides a meaningful total return floor.
167.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
22.84%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.65

Recent News

Reuters
Mar 17, 2026

Big drugmakers must face US overcharge claims on medications for low-income patients

By Jonathan Stempel March 17 (Reuters) - A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 17, 2026

AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

AbbVie slips below its 50-day SMA, signaling short-term weakness, but strong drug growth and a solid long-term uptrend may keep investors holding or buying dips

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU

AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding its blockbuster oncology footprint.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 17, 2026

Imfinzi EU Approval Expands AstraZeneca Gastric Cancer Reach For Investors

AstraZeneca has received European Union approval for Imfinzi in combination with FLOT chemotherapy for early-stage and locally advanced gastric and gastroesophageal cancers. The decision is based on positive overall survival and event free survival data from the Phase III MATTERHORN trial. The approval significantly broadens AstraZeneca's oncology offering, a segment that accounts for over 40% of company revenue. For investors tracking AstraZeneca (LSE:AZN), this approval adds a new...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
24/7 Wall St.
Mar 17, 2026

Why This Dimensional International ETF Belongs in Every Retiree’s Core Portfolio

Retirees building international exposure face a familiar dilemma: broad index funds offer diversification but treat every stock equally regardless of quality. Dimensional International Core Equity Market ETF (NYSEARCA:DFAI) tilts toward smaller companies, lower-priced stocks relative to their fundamentals, and higher-profitability businesses within the international universe. The goal is capturing long-run return premiums that academic research ... Why This Dimensional International ETF Belongs

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.